Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle

Meanwhile, pharmaceutical companies would stand to make a lot more money.
Originally published on 09/29/2020 in Bloomberg Opinion

Early in President Trump's term, he said pharmaceutical companies' prices were so high they were 'getting away with murder.'

However, drug prices rose anyway. The Associated Press reported that in 2018, for every one drug price that fell, 96 other drug prices went up. President Trump's administration proposed a wave of new federal policies in a last-ditch effort to deliver on his campaign promises. Dr. Bach lays out the proposals and describes how the strategies in these proposals would only enrich the pharmaceutical industry, and raise costs for taxpayers. 

  1. In June, the Trump administration proposed a loophole that would let drug companies give bigger discounts to their preferred customers than Medicaid. By revoking price protections, it would raise costs for the vital program.  
  1. When it came time to negotiate the price of Remdesivir in June, HHS committed US hospitals to pay about $3200 per treatment – 33% more than the price the company announced it would charge other developed countries. 
  1. The president signed an executive order meant to block insurance companies from collecting rebates from drug companies after beneficiaries fill their prescriptions. In effect, insurance premiums for everyone would increase, regardless of whether they buy Part D insurance or get insurance through their employer or an insurance-exchange plan. 
  1. Trump announced he will let people import lower-priced drugs from Canada, however he has not outlined a formal plan. 
  1. The president announced that Medicare would pay no more for drugs than other high income countries do. In reality, drug companies can still charge doctors and hospitals high prices, but the government and taxpayers will have to compensate.  
  1. Trump promised to send Medicare beneficiaries $200 cards to help pay for their medicines. However, giving them money to help defray the cost would only encourage drug makers to raise their prices more.  

Read the full piece here.


Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Xeljanz, the FDA, and nine years of patient harm
Quantifying population-level adverse events in the near decade between when safety concerns were identified and FDA action
Drug Pricing Lab 05/31/2022
Atypical antipsychotics: Decades of use, unfathomable harms
Using attributable risk calculations to quantify how many premature deaths resulted from atypical antipsychotic use in the elderly
Drug Pricing Lab 05/31/2022
Medicare Part B Premium Dynamics Explained
The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.
Milliman 12/23/2021
Comparing Factors that Influence Pharmaceutical Pricing and Access in the…
Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.
Drug Pricing Lab 12/20/2021
Biosimilars in Medicare Part D: pricing dynamics and considerations
The Drug Pricing Lab engaged Milliman to prepare a report summarizing the pricing dynamics affecting utilization of biosimilars in the current Medicare Part D marketplace and under the proposed Part D benefit design in the Build Back Better Act.

This report was commissioned by the Drug Pricing Lab.
Milliman 12/14/2021
Evaluating Industry’s Drug Pricing Claims
A closer look at three of PhRMA’s most cited talking points.
Drug Pricing Lab 11/18/2021
Mapping conflict of interests: scoping review
A scoping review of the literature to identify all known ties between the medical product industry and the parties and activities in the healthcare ecosystem.
Drug Pricing Lab 11/03/2021
Production Plus Profit Pricing (P-quad) FAQ
What A Waste! The National Academy Of Medicine’s Report On…
Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.
Health Affairs Blog 07/09/2021
Medicare Must Study Unproven, Expensive Alzheimer’s Drug
Medicare cannot indiscriminately cover the cost of Aduhelm for the treatment of Alzheimer's disease without first evaluating whether it truly works.
Bloomberg Opinion 06/15/2021
Value-Based Management of Specialty Drugs: Practical Considerations and Implications for…
Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.
AJMC 05/13/2021
Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle
Meanwhile, pharmaceutical companies would stand to make a lot more money.
Bloomberg Opinion 09/29/2020

Stay up to date on our work and news